← Therapeutics
Details checkedClinical trial listing onlyCheckedregistry
Curcumin-phosphatidylcholine subjective tinnitus study
Also known as: Curcumin-Phosphatidylcholine, Highly bioavailable curcumin tinnitus study
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Biologic/Nutraceutical
Stage
Not applicable
Status
Unknown
Target Gene
—
Route / Mode
Oral
Confidence
84%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
United States
Population
adult, tinnitus
Trial IDs
1
Mechanism
Randomized double-blind placebo-controlled study of curcumin-phosphatidylcholine plus boswellia-phosphatidyl capsules for subjective tinnitus.
Indications
Notes
Registry-verified institution-led tinnitus study. Current registry status is unknown; no company-sponsored hearing therapeutic program was verified.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...
IDs: NCT04800107
Key Events
2021-01-06
Clinical Trials (1)
Data Checks
institution-led-studyregistry-only-evidencecurrent-status-unknown-in-registrynot-confirmed-current-product
Related Programs
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
OTO-313 by Otonomy
Company: Otonomy · Small Molecule · Phase 2
AM-101 by Auris Medical and Altamira
Company: Altamira Therapeutics · Small Molecule · Phase 3
NHPN-1010
Company: Otologic Pharmaceutics · Small Molecule · Phase 1
OTO-104 (dexamethasone) by Otonomy
Company: Otonomy · Steroid/Anti-inflammatory · Phase 3